Search results
Results From The WOW.Com Content Network
The biomarkers can be used to diagnose Alzheimer's disease (AD) in a very early stage, but they also provide objective and reliable measures of disease progress. It is imperative to diagnose AD disease as soon as possible, because neuropathologic changes of AD precede the symptoms by years. [ 1 ]
The NINCDS-ADRDA Alzheimer's Criteria were proposed in 1984 by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (now known as the Alzheimer's Association) and are among the most used in the diagnosis of Alzheimer's disease (AD). [1]
Therefore, early and accurate diagnosis of dementia and staging can be essential to proper clinical care. Without the ability to reliably assess dementia across the board, the misuse of anti-dementia compounds could have negative consequences, such as patients receiving the wrong medication, or not receiving treatment in the early stages of ...
For premium support please call: 800-290-4726 more ways to reach us
AGNPs can be found practicing in a variety of medical facilities including hospices, long-term care facilities, hospitals, home-based care, correctional institutes and primary practices. [4] The scope of practice varies from state to state because nurse practice laws and regulations are specific to the state the nurse practitioner practices in. [5]
With no cure for Alzheimer’s, an early diagnosis allows patients to access help and support. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 ...
Imagine: You and your sister are 66-year-old twins on Medicare who share the same family history of Alzheimer’s disease, making an early diagnosis critical for long-term planning and preventive ...
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia. It is one of the most widely used cognitive scales in clinical trials [ 1 ] and is considered to be the “gold standard” for assessing antidementia treatments.